DRG presented DRG:HYBRiD-XL at MEDICA 2009
-Unique, fully-automatic, random access analyzer for immunoassays and clinical chemistry to be available for use in 2011-
The DRG:HYBRiD-XL fully automated, random access analyzer was unveiled at the 2009 MEDICA international conference in Dusseldorf, Germany, to great interest. The laptop analyzer, ideal for medium-sized and small laboratories, provides diagnostic services to hospitals, clinics and large medical practice facilities. The DRG:HYBRiD-XL will allow laboratories to conduct specific testing on-site, providing for faster and more accurate test results with greater convenience.
The 2009 MEDICA international conference, held in November, provided an ideal venue for the DRG:HYBRiD-XL's unveiling. As the largest yearly medical trade event in Europe, MEDICA attracted over 138,000 visitors from nearly 100 countries eager to learn of current and future trends in Diagnostics, R&D, and in-patient and out-patient care.
An exciting new product for many of MEDICA's attendees, the DRG:HYBRiD-XL is also ideal for high work-load labs performing routine and niche diagnostic parameters on large automatic equipment. The DRG system will offer the option of running 40 different tests on up to 20 patient samples simultaneously. The DRG analyzer may also be programmed to measure 40 different tests from one patient sample, or even one or more tests from up to 20 samples.
The unique construction of the DRG:HYBRiD-XL allows for the flexibility to combine diagnostic panels that can run at the same time. For example, a lab may now run cardiology and oncology panels concurrently. Additionally, the DRG analyzer has the ability to detect antigens and antibodies in serum, plasma or saliva.
To work with the unique design of the analyzer, DRG will offer packages of 24, 60 and 120 tests for flexibility and customization depending on test requirements. The small package size of the cartridges, and thus the reagents included, reduces the need for waste disposal.
The DRG:HYBRiD-XL is designed to provide ease of use in all aspects of testing. The analyzer is controlled by an easy-to-read touch screen monitor run by software that offers simple user navigation. Depending upon the test type, the results can be read in as little as 10 minutes.
Currently DRG is in the process of validating a wide range of possible tests for use in a variety of areas of medical expertise. Anticipated availability of the DRG:HYBRiD-XL is 2011. For more information, please contact DRG International at (908) 233-2079 or visit www.drg-international.com.
Mrs. Elke Geacintov, Executive Vice President of DRG International, Mr. Wilhelm Saenger, General Manager of DRG Instruments GmbH, and Dr. Cyril Geacintov, President and CEO of DRG International, unveiling the DRG:HYBRiD-XL at Medica 2009